Receptors, signalling and cardiac pharmacology

 
Finn Olav Levy<br>Group leader
Finn Olav Levy
Group leader

Challenges
Patients with heart failure (HF) have high morbidity and poor prognosis. To develop new treatments, we need to understand the mechanisms of myocardial function in normal and failing hearts and the development of HF. Several receptors (e.g. beta-adrenoceptors (βAR), 5-HT4 serotonin receptors) increase cardiac contractile function through the cAMP signalling system. This response is energetically expensive and therefore detrimental in the long term and should be avoided in HF. Blocking βARs is therefore one of the best treatments of HF. While increased understanding can provide novel ways to reduce these signalling pathways, understanding of other types of cardiac signalling may reveal novel methods to improve cardiac function in heart failure. Recent development in understanding of receptor function has important implications also for understanding and treatment of other diseases.

Projects

  • Importance of serotonin receptors in heart failure
  • Signalling mechanisms regulating contractile function in normal and failing hearts
  • Compartmentation of receptor-mediated cAMP and cGMP signalling in normal and failing hearts. Implications for treatment of heart failure
  • Importance of increased calcium efficiency in the failing heart
  • New understanding of receptor function: Functional selectivity and receptor-G protein interaction

Contact information:
Group leader Professor Finn Olav Levy Department of Pharmacology University of Oslo and Oslo University Hospital PO Box 1057 Blindern NO-0316 Oslo, Norway, Tel: +47 22840237 Fax: +47 22840202 E-mail: f.o.levy@medisin.uio.no